Immatics (IMTX) Interest Expenses (2019 - 2025)
Immatics recorded quarterly Interest Expenses of -$599482.4 in Q4 2025, down 77.44% quarter-over-quarter from -$337856.9 in Q3 2025, and down 113.95% year-over-year from $4.3 million in Q4 2024.
Immatics' Interest Expenses history runs 7 years deep, the most recent figure standing at -$599482.4 for Q4 2025.
- In Q4 2025, Interest Expenses fell 113.95% year-over-year to -$599482.4; the TTM figure through Dec 2025 stood at -$40.7 million (down 284.67% YoY), while the FY2025 annual figure was -$41.4 million, down 2834.63% from the prior year.
- Interest Expenses came in at -$599482.4 for Q4 2025 at Immatics, down from -$337856.9 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $4.3 million in Q4 2024 to a low of -$25.8 million in Q2 2025.
- A 5-year average of -$3.6 million and a median of -$746476.8 in 2024 frame the typical range for Interest Expenses.
- Across the five-year window, Interest Expenses jumped 363.75% in 2021 and tumbled 7749.43% in 2025, its largest moves.
- Immatics' Interest Expenses stood at -$372934.5 in 2021, then slumped by 1631.44% to -$6.5 million in 2022, then jumped by 51.78% to -$3.1 million in 2023, then soared by 237.99% to $4.3 million in 2024, then tumbled by 113.95% to -$599482.4 in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered -$599482.4, -$337856.9, and -$25.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | -599,482.41 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -599,482.41 |
| Dec 31, 2025 | -599,482.41 |
| Sep 30, 2025 | -337,856.92 |
| Sep 30, 2025 | -337,856.92 |
| Jun 30, 2025 | -25.78 Mn |
| Jun 30, 2025 | -25.78 Mn |
| Mar 31, 2025 | -14.03 Mn |
| Mar 31, 2025 | -14.03 Mn |
| Dec 31, 2024 | 4.30 Mn |
| Dec 31, 2024 | 4.30 Mn |
| Sep 30, 2024 | -13.83 Mn |
| Sep 30, 2024 | -13.83 Mn |
| Jun 30, 2024 | -328,450.71 |
| Jun 30, 2024 | -328,450.71 |
| Mar 31, 2024 | -735,466.92 |
| Mar 31, 2024 | -735,466.92 |
| Dec 31, 2023 | -3.11 Mn |
| Dec 31, 2023 | -3.11 Mn |
| Sep 30, 2023 | -1.71 Mn |
| Sep 30, 2023 | -1.71 Mn |
| Jun 30, 2023 | -1.25 Mn |
| Jun 30, 2023 | -1.25 Mn |
| Mar 31, 2023 | -3.77 Mn |
| Mar 31, 2023 | -3.77 Mn |
| Dec 31, 2022 | -6.46 Mn |
| Dec 31, 2022 | -6.46 Mn |
| Sep 30, 2022 | -429,524.86 |
| Sep 30, 2022 | -429,524.86 |
| Jun 30, 2022 | -434,292.07 |
| Jun 30, 2022 | -434,292.07 |
| Mar 31, 2022 | -1.25 Mn |
| Mar 31, 2022 | -1.25 Mn |
| Dec 31, 2021 | -372,934.53 |
| Dec 31, 2021 | -372,934.53 |
| Sep 30, 2021 | -201,658.13 |
| Sep 30, 2021 | -201,658.13 |
| Jun 30, 2021 | -757,486.73 |
| Jun 30, 2021 | -757,486.73 |
| Mar 31, 2021 | 84,436.53 |
| Mar 31, 2021 | 84,436.53 |
| Dec 31, 2020 | -12.22 Mn |
| Dec 31, 2020 | -12.22 Mn |
| Sep 30, 2020 | -7.85 Mn |
| Sep 30, 2020 | -7.85 Mn |
| Jun 30, 2020 | -2.38 Mn |
| Jun 30, 2020 | -2.38 Mn |
| Mar 31, 2020 | -32,014.23 |
| Mar 31, 2020 | -32,014.23 |
| Dec 31, 2019 | 363,059.16 |
| Dec 31, 2019 | 363,059.16 |
| Sep 30, 2019 | -67,876.53 |
| Sep 30, 2019 | -67,876.53 |
| Jun 30, 2019 | -521,368.54 |
| Jun 30, 2019 | -521,368.54 |